What is the difference between sunitinib and lenvatinib?

Sunitinib and lenvatinib are multi-target tyrosine kinase inhibitors that are widely used in the targeted treatment of various tumors. Although the two have some overlap in their mechanisms of action and indications, they have significant differences in target selection, clinical application, pharmacological properties, and side effects. Understanding these differences is critical to rational clinical use of drugs and the development of patient treatment plans. The following will provide a detailed analysis of the differences between sunitinib and lenvatinib from multiple perspectives.

First of all, from the perspective of mechanism of action and target spectrum, sunitinib mainly targets platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR), c-KIT, FLT3 and RET and other tyrosine kinases. It exerts anti-tumor effects by inhibiting the activity of these kinases, blocking tumor angiogenesis and tumor cell proliferation. Lenvatinib is a newer generation multi-target kinase inhibitor, with targets including VEGFR1-3, FGFR1-4, PDGFRα, RET and c-KIT, etc., especially the inhibition of the fibroblast growth factor receptor (FGFR) family is more significant. FGFR plays an important role in tumor angiogenesis and tumor microenvironment regulation. Lenvatinib's inhibitory ability in this regard gives it unique advantages in certain tumor types.

Secondly, from the perspective of clinical indications, both are approved for the treatment of a variety of solid tumors, but the specific indications are different. Sunitinib was first approved for the treatment of renal clear cell carcinoma, gastrointestinal stromal tumor (GIST), pancreatic neuroendocrine tumors, etc. It is also one of the important drugs in the first-line treatment of advanced renal cancer. Lenvatinib is mainly used for thyroid cancer (especially refractory differentiated thyroid cancer), hepatocellular carcinoma (when used in combination with sorafenib) and renal cancer. In recent years, lenvatinib has also been approved for use in combination with immune checkpoint inhibitors to treat renal cancer and certain endometrial cancers, showing strong potential for clinical application expansion.

In terms of pharmacokinetics, sunitinib is absorbed quickly after oral administration, with a half-life of approximately 40-60 hours. Its metabolism is mainly through the CYP3A4 enzyme system of the liver. Special attention should be paid to drug-drug interactions. Lenvatinib is also absorbed quickly after oral administration, with a half-life of approximately 28hour, also dependent on liver enzyme metabolism. Both require attention to liver function status, as abnormal liver function may affect drug metabolism and safety. Lenvatinib targets FGFR, so its toxicity spectrum and safety monitoring focus are different from those of sunitinib.

In terms of side effects, common adverse reactions of sunitinib include fatigue, diarrhea, hypertension, hand-foot syndrome, thyroid dysfunction, etc. In addition to similar hypertension, fatigue, and diarrhea, lenvatinib is more likely to cause proteinuria, thyroid dysfunction, and liver function damage. In clinical application, both blood pressure, liver and kidney function and endocrine indicators need to be closely monitored, and the medication regimen should be adjusted in a timely manner. When lenvatinib is combined with immunotherapy, monitoring of immune-related adverse reactions is particularly important.

In addition, the dosing regimen and dose adjustment are also different between the two. Sunitinib is usually taken orally once daily, and the dose is adjusted based on specific indications and patient tolerance. Common doses range from 37.5 mg to 50 mg. The dosage of lenvatinib varies according to the indications, ranging from 4mg to 24mg once a day. Some patients need to adjust the dose based on liver function or adverse reactions. During treatment, doctors will flexibly adjust the use of the two drugs based on the patient's specific situation, efficacy and side effects.

Taken together, although sunitinib and lenvatinib are both multi-target tyrosine kinase inhibitors, they have their own characteristics in terms of target selection, clinical indications, pharmacological properties and adverse reaction management. As an earlier targeted drug on the market, sunitinib has a solid clinical foundation in the treatment of renal cancer and GIST; while lenvatinib has shown broad application prospects in multiple tumor types due to its unique inhibitory effect on FGFR and its potential for combination immunotherapy. When using these two drugs, patients should strictly follow the doctor's guidance, combine individualized diagnosis and treatment plans, and rationally select and adjust medication to maximize treatment benefits and reduce the risk of adverse reactions.

Reference materials:https://www.sutent.com/